NUDT21 Antibody

What is NUDT21 and what biological functions does it perform?

NUDT21 (Nudix Hydrolase 21, also called CFIm25 or Cpsf5) is an RNA binding protein that functions as a component of the pre-mRNA cleavage and polyadenylation complex . It plays a critical role in alternative polyadenylation (APA), a post-transcriptional modification that generates transcript isoforms with different 3' UTR lengths. NUDT21 recognizes and binds to specific UGUA motifs, which are significantly enriched near distal polyadenylation sites within the 3' UTRs of its target genes . Through this binding activity, NUDT21 influences gene expression by regulating mRNA stability, localization, and translation efficiency. In cellular contexts, NUDT21 has been implicated in cell fate transitions, stem cell pluripotency, and cancer progression .

How is NUDT21 expression typically detected in experimental settings?

NUDT21 expression can be detected through multiple complementary techniques:

• Immunohistochemistry (IHC): This method allows visualization of NUDT21 protein in paraffin-embedded tissue sections. Standard protocols involve tissue fixation, antigen retrieval using citrate buffer, hydrogen peroxide blocking, and incubation with NUDT21-specific antibodies. Expression can be quantified using a scoring system based on percentage of stained cells (0: 0% stained cells; 1: 1-50% stained cells; 2: 51-100% stained cells) .

• Western blotting: This technique provides quantitative assessment of NUDT21 protein levels in cell or tissue lysates with size verification.

• RT-qPCR: For mRNA expression analysis, RT-qPCR can be employed to quantify NUDT21 transcript levels across different samples .

• Immunofluorescence: Allows subcellular localization studies of NUDT21 protein with higher resolution than IHC and enables co-localization studies with other proteins .

What factors should be considered when selecting a NUDT21 antibody for research?

When selecting a NUDT21 antibody, researchers should consider:

• Antibody specificity: Validate using positive controls (tissues/cells known to express NUDT21, such as MCF-10A cells) and negative controls (NUDT21 knockdown samples) .

• Application compatibility: Different antibodies perform optimally in specific applications (IHC, Western blot, immunoprecipitation, or ChIP). Select antibodies validated for your intended application.

• Epitope location: Antibodies recognizing different epitopes may yield different results, especially if studying specific NUDT21 domains or interactions.

• Species reactivity: Ensure compatibility with your experimental model organism. NUDT21 is highly conserved across mammals, but antibody reactivity should be confirmed.

• Monoclonal versus polyclonal: Monoclonal antibodies offer higher specificity but may be sensitive to epitope modifications, while polyclonal antibodies provide robust detection but potentially higher background.

What are the optimal conditions for NUDT21 immunohistochemistry in tissue samples?

Based on published protocols, optimal IHC conditions for NUDT21 detection include:

• Fixation and embedding: Standard formalin fixation and paraffin embedding are suitable.

• Section thickness: Approximately 4 μm thick sections are recommended .

• Antigen retrieval: Heat-induced epitope retrieval using 0.01M citrate buffer (pH 6.0) for 3 minutes at boiling temperature .

• Blocking steps:

  • Block endogenous peroxidase with hydrogen peroxide

  • Block non-specific binding with normal goat serum

• Antibody dilution: Optimal dilution varies by antibody source; titration experiments are recommended.

• Detection system: Standard visualization systems such as DAB (3,3'-diaminobenzidine) are suitable for NUDT21 detection.

• Scoring system: A 0-2 scoring system based on percentage of positively stained cells is commonly used:

  • Score 0: 0% stained cells (no expression)

  • Score 1: 1-50% stained cells (low expression)

  • Score 2: 51-100% stained cells (high expression)

How does NUDT21 expression differ between normal and cancerous tissues?

NUDT21 expression patterns vary depending on the cancer type, suggesting context-dependent roles:

In breast cancer:

• NUDT21 expression is significantly lower in breast cancer tissues compared to benign breast tissues .

• Immunohistochemistry studies have shown positive NUDT21 expression in 74% of benign breast tissues versus only 42% of breast cancer tissues (p < 0.001) .

• The reduced expression correlates with unfavorable clinical parameters including larger tumor size, advanced TNM stage, and lymph node metastasis .

In pancreatic adenocarcinoma:

• NUDT21 appears to play a role in pancreatic adenocarcinoma progression through immune infiltration and signaling pathway modulation .

Expression across cell lines:

• Various breast cancer cell lines (MDA-MB-468, BT-549, MCF-7, MDA-MB-231, SKBR3, T47D) show differential NUDT21 expression compared to normal breast epithelial cells (MCF-10A) .

What is the prognostic significance of NUDT21 expression in cancer patients?

In breast cancer, NUDT21 expression has significant prognostic implications:

This survival correlation suggests NUDT21 may function as a tumor suppressor in breast cancer.

How can NUDT21 antibodies be utilized to identify protein-protein interactions?

NUDT21 antibodies are valuable tools for characterizing protein-protein interactions through several approaches:

• Co-immunoprecipitation (Co-IP): NUDT21 antibodies can be used to pull down NUDT21 protein complexes from cell lysates, followed by mass spectrometry analysis or Western blotting to identify interaction partners. This approach has successfully identified CPSF6 as a direct interaction partner of NUDT21 in breast cancer cells .

• Reciprocal Co-IP: To confirm interactions, researchers can perform reverse experiments using antibodies against suspected binding partners (such as CPSF6) to pull down complexes and then probe for NUDT21.

• Proximity ligation assay (PLA): This technique allows visualization of protein-protein interactions in situ with high sensitivity, using primary antibodies against NUDT21 and its potential interaction partners.

• CLIP-seq (Cross-linking immunoprecipitation followed by sequencing): For identifying RNA targets of NUDT21, CLIP-seq using NUDT21 antibodies can map binding sites across the transcriptome, as demonstrated in studies showing NUDT21 binding to UGUA motifs near distal polyadenylation sites .

• Immunofluorescence co-localization: Dual staining with NUDT21 antibodies and antibodies against potential interaction partners can provide initial evidence of protein associations in cellular compartments.

What experimental approaches are recommended for studying NUDT21's role in alternative polyadenylation?

To investigate NUDT21's function in alternative polyadenylation (APA), researchers can employ these approaches:

• PolyA site-sequencing (PAS-seq): This method identifies differential polyadenylation site usage genome-wide following NUDT21 modulation. Studies have revealed that NUDT21 suppression causes a massive shift from distal to proximal polyA sites (1,562 transcripts affected compared to 59 in control conditions) .

• NUDT21 binding site analysis: Computational analysis of UGUA motif distribution within 3'UTRs has shown significant enrichment near distal polyA sites compared to proximal sites in NUDT21 target genes .

• Expression modulation experiments:

  • Knockdown: siRNA or shRNA targeting NUDT21

  • Overexpression: Transfection with NUDT21 expression constructs

  • Combined with RNA-seq and 3'RACE to assess changes in APA patterns

• Functional validation of APA targets:

  • 3'UTR reporter assays to confirm direct regulation

  • Rescue experiments using constructs with mutated UGUA motifs

  • Protein expression analysis to determine which APA changes affect protein output

• Integration with CLIP-seq data: Comparing APA changes upon NUDT21 knockdown with CLIP-seq data for NUDT21 and cofactors like CFIm68 helps identify direct versus indirect targets .

How does NUDT21 knockdown or overexpression affect cellular phenotypes?

NUDT21 modulation leads to significant changes in cellular behavior that can be assessed through various functional assays:

Effects of NUDT21 knockdown:

• Proliferation: Enhanced cell proliferation in breast cancer cells, measurable through MTT assays and colony formation assays .

• Migration and invasion: Increased cell migration and invasion capabilities, detectable via transwell assays .

• EMT: Promotion of epithelial-mesenchymal transition, assessed through changes in EMT marker expression .

• Stem cell reprogramming: Dramatic enhancement (up to 30-fold) in the generation of alkaline phosphatase (AP) positive iPSC colonies .

• Cell fate transitions: Facilitated transdifferentiation into trophoblast stem cells .

• Stem cell marker expression: Accelerated and increased expression of pluripotency markers including SSEA1, EPCAM, OCT4-GFP, Nanog, Esrrb and Cdh1 .

Effects of NUDT21 overexpression:

• Proliferation: Inhibited cell proliferation in breast cancer cells .

• Migration and invasion: Reduced cell migration and invasion capabilities .

• EMT: Suppression of epithelial-mesenchymal transition .

• Stem cell differentiation: Impaired differentiation of myeloid precursors and embryonic stem cells .

These phenotypic effects should be carefully assessed through appropriate experimental methods, including proliferation assays, migration and invasion assays, Western blotting for EMT markers, and stem cell marker detection.

How can researchers investigate the NUDT21/CPSF6 signaling pathway in cancer models?

The NUDT21/CPSF6 pathway can be studied through these methodological approaches:

• Expression correlation analysis:

  • Assess NUDT21 and CPSF6 expression levels in matched cancer and normal tissues

  • Determine their correlation with clinicopathological features and survival outcomes

  • Co-expression analysis in tissue microarrays or patient cohorts

• Molecular interaction characterization:

  • Co-immunoprecipitation to verify direct interaction between NUDT21 and CPSF6

  • Domain mapping to identify interaction regions

  • In vitro binding assays with purified proteins

• Functional relationship assessment:

  • CPSF6 knockdown in NUDT21-suppressed cells to assess rescue of phenotypes

  • Double knockdown experiments to determine epistatic relationships

  • Analysis showing CPSF6 knockdown reverses NUDT21 expression-induced cancer cell migration and invasion

• Downstream target identification:

  • RNA-seq and protein analysis following manipulation of pathway components

  • Pathway enrichment analysis to identify affected cellular processes

  • Validation of key targets through reporter assays

• In vivo models:

  • Xenograft models with NUDT21 and/or CPSF6 manipulation

  • Patient-derived xenografts treated with pathway modulators

  • Genetically engineered mouse models with targeted pathway alterations

What are common challenges in NUDT21 antibody applications and how can they be addressed?

Researchers may encounter several challenges when working with NUDT21 antibodies:

• High background in immunohistochemistry:

  • Solution: Optimize blocking conditions using different blocking reagents (BSA, normal serum)

  • Increase washing duration and frequency

  • Titrate primary antibody concentration

  • Use more specific detection systems

• Weak or absent signal:

  • Solution: Optimize antigen retrieval methods (test different buffers, pH, and heating times)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal amplification systems

  • Verify tissue fixation conditions (overfixation can mask epitopes)

• Inconsistent results between experimental replicates:

  • Solution: Standardize tissue processing and staining protocols

  • Use positive and negative controls in each experiment

  • Implement quantitative scoring systems with blinded assessment by multiple observers

  • Document detailed protocols including lot numbers of antibodies

• Discrepancies between mRNA and protein expression:

  • Solution: Perform parallel RT-qPCR and Western blot/IHC analyses

  • Consider post-transcriptional regulation mechanisms

  • Validate findings using multiple antibodies targeting different epitopes

• Cross-reactivity with other proteins:

  • Solution: Validate specificity using NUDT21 knockout or knockdown samples

  • Perform peptide competition assays

  • Compare results from multiple antibodies recognizing different epitopes

How can researchers address conflicting data about NUDT21's role across different cancer types?

NUDT21 appears to play context-dependent roles across different cancers, functioning as a tumor suppressor in some contexts while showing oncogenic properties in others . To address conflicting data:

• Comprehensive literature review:

  • Systematically compare methodologies used across studies

  • Evaluate differences in experimental models (cell lines, patient cohorts)

  • Consider ethnic and demographic differences in patient populations

• Multi-omics approach:

  • Integrate genomic, transcriptomic, and proteomic data

  • Analyze alternative polyadenylation patterns across cancer types

  • Examine pathway activation signatures in different contexts

• Conditional knockout/knockin models:

  • Develop tissue-specific and inducible models to study NUDT21 function

  • Compare effects in different tissue backgrounds

  • Assess temporal effects during cancer progression

• Clinical correlation studies:

  • Analyze larger patient cohorts with comprehensive clinical data

  • Stratify by cancer subtypes, stages, and molecular signatures

  • Address discrepancies seen in different cohorts such as TCGA versus other datasets

• Interaction network analysis:

  • Map NUDT21 interaction partners across different tissues

  • Identify tissue-specific co-factors that may alter NUDT21 function

  • Determine if differential expression of binding partners explains context-dependent roles

What emerging technologies could enhance NUDT21 research beyond traditional antibody-based methods?

Several cutting-edge technologies can complement and extend antibody-based NUDT21 research:

• CRISPR-Cas9 genome editing:

  • Generation of NUDT21 knockout cell lines for antibody validation

  • Knock-in of tagged NUDT21 variants for live-cell imaging

  • Domain-specific mutations to dissect functional regions

• Single-cell analysis technologies:

  • Single-cell RNA-seq to examine cell-specific NUDT21 expression patterns

  • Single-cell ATAC-seq to correlate with chromatin accessibility

  • Mass cytometry (CyTOF) for high-dimensional protein analysis

• Spatial transcriptomics and proteomics:

  • In situ sequencing to map NUDT21 mRNA in tissue context

  • Imaging mass cytometry for spatial protein expression patterns

  • Multiplexed ion beam imaging (MIBI) for highly multiplexed protein detection

• Nanobody and aptamer technologies:

  • Development of NUDT21-specific nanobodies for live-cell applications

  • RNA aptamers for detection of NUDT21 in living systems

  • Intrabodies to modulate NUDT21 function in specific subcellular compartments

• Computational approaches:

  • Machine learning algorithms to predict NUDT21 targets and functions

  • Network analysis to position NUDT21 in cellular pathways

  • Integration of multi-omics data to create comprehensive models of NUDT21 function

How can researchers design experiments to investigate NUDT21's potential as a therapeutic target?

To evaluate NUDT21's therapeutic potential, researchers should consider:

• Target validation studies:

  • Conditional expression systems in relevant cancer models

  • Correlation of NUDT21 modulation with clinical outcomes

  • Identification of synthetic lethal interactions

• Small molecule inhibitor development:

  • High-throughput screens for compounds affecting NUDT21 binding to RNA

  • Structure-based drug design targeting the NUDT21-UGUA interaction

  • Evaluation of compounds that modulate NUDT21-CPSF6 interaction

• Therapeutic combination strategies:

  • Testing NUDT21 modulation in combination with standard therapies

  • Identifying synergistic drug combinations through matrix screening

  • Determining mechanisms of potential resistance

• Biomarker development:

  • Identification of patient populations likely to respond to NUDT21-targeted therapies

  • Development of companion diagnostics for patient stratification

  • Monitoring tools for treatment response

• Delivery systems for RNA therapeutics:

  • siRNA or antisense oligonucleotides targeting NUDT21

  • Nanoparticle formulations for tumor-specific delivery

  • Assessment of duration of effect and potential for resistance